At an AHA-sponsored briefing today on Capitol Hill, hospital leaders called for changes in Medicare’s Hospital Readmissions Reduction Program. Michael Langberg, M.D., senior vice president of medical affairs and chief medical officer at Cedars-Sinai in Los Angeles, said hospitals shouldn’t be “penalized for resources and functions they cannot control,” including sociodemographic factors, such as poverty and lack of supportive services in the community. Leaders from Ochsner Health System in New Orleans and Presence Health in Chicago also participated in the briefing. The panelists also urged Congress to support the Establishing Beneficiary Equity in the Hospital Readmission Program Act, S. 688/H.R. 1343. The AHA-supported bill would require the Centers for Medicare & Medicaid Services to account for patient sociodemographic status when making risk adjustments to the readmissions penalties. At the briefing, the AHA also released a new TrendWatch report showing that the national readmission rate is declining, but reducing readmissions is a “complex undertaking because not all readmissions can or should be prevented; indeed, some are planned as part of sound clinical care.”

Related News Articles

Headline
The Centers for Medicare & Medicaid Services has extended the deadline for submitting third-quarter data to the Post-Acute Care Quality Reporting Program.
Headline
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation.
Headline
Hospitals and clinicians are seeing fewer flu patients this season than in other recent years, the Centers for Disease Control and Prevention reports.
Insights and Analysis
Please consider applying for the award and sharing how your organization is improving health equity and value.
Headline
Members of the pharmaceutical distribution supply chain, including dispensers such as hospitals and pharmacies, can apply through March 11 to participate in a…
Headline
The U.S. District Court for the Western District of Pennsylvania has entered a consent decree prohibiting Ranier’s Rx Laboratory Inc. from manufacturing or…